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Invasive candidiasis (IC) poses a major public health problem worldwide. Despite the 
introduction of new antifungal agents and changes in clinical practices, its morbidity and 
mortality rates and healthcare costs remain persistently high. This is mainly because of the 
serious underlying conditions of infected patients (critically ill or severely immunocompromised 
patients) and the difficulties encountered in early diagnosing this opportunistic mycosis and 
initiating prompt and appropriate antifungal therapy. In the light of this great clinical challenge, 
the past decades have witnessed the development of diverse early detection and therapeutic 
intervention strategies aimed at minimizing the clinical impact and economic burden of this 
healthcare-associated infection caused by Candida species. Here, we review the currently 
available methods for IC diagnosis. These encompass (i) gold standard methods (fungal culture 
and tissue histopathology), (ii) pathogen-derived biomarker detection tests (PCR, protein 
antigens, mannan, ß-D-glucan and D-arabinitol-based assays), (iii) host-derived biomarker 
detection tests (Candida albicans germ tube antibodies or CAGTA, anti-mannan antibodies, other 
infection-specific antibodies, procalcitonin, serum amyloid A, interleukin 17, interleukin 23 and 
transforming growth factor ß-based assays), (iv) clinical prediction algorithms (Candida score, 
colonization index and other prediction rules), and (v) leading-edge molecular, proteomic and 
immunomic technologies (such as peptide nucleic acid-fluorescent in situ hybridization or PNA-
FISH, T2 magnetic resonance or T2Candida assay, and matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry or MALDI-TOF MS, among others). 
Their strengths, utility, limitations as well as combined use to assist in the diagnosis of this life-





Invasive candidiasis (IC) is the most common fungal infection acquired in healthcare-
associated settings (particularly in intensive care, surgery, transplant, hematology-oncology, burn 
and neonate units) [1-3]. This nosocomial infection is directly linked to advances in medical care 
directed towards prolonging patient survival [2, 4]. These include important risk factors for IC, 
such as the wider use of broad-spectrum antibiotics, more aggressive immunosuppressive 
treatments (new chemotherapeutic, cytotoxic or immunomodulatory agents, and solid organ or 
hematopoietic stem cell transplantation), invasive medical devices (central vascular catheters and 
ventilators), total parenteral nutrition, hemodialysis, major surgical procedures and intensive care, 
to name but a few [2, 5-7]. Although this healthcare-associated fungal infection can be acquired 
exogenously through the hands of hospital workers or contaminated solutions, most cases of IC 
are endogenous in origin and stem from the patient microbiota and opportunistic nature of its 
etiological agents [8-9]. 
This opportunistic mycosis is caused by several Candida species. These are common 
members of the normal microbiota on the oropharyngeal cavity, gastrointestinal tract and vagina 
of many healthy individuals [10-12]. However, these harmless commensal fungi can take 
advantage of an opportunity not normally available, induce key virulence factors, and cause 
invasive infection [4, 13]. The chance that allows them to evolve into harmful opportunistic 
pathogens is closely related to alterations in the normal microbiota composition (by the repeated 
or long-term use of broad-spectrum antibiotics), disruptions in the natural cutaneous and 
gastrointestinal barriers (by invasive procedures, burns or wounds), and impairments of the 
immune system (by disease o immunosuppressive therapies) [4, 7, 14-15]. 
Invasive forms of Candida infection encompass candidemia (bloodstream infection) and 
deep-seated candidiasis (infection involving other normally sterile body fluids and tissues) [1, 4, 
5 
 
16]. Candidemia is often associated with a sepsis syndrome (similar to severe bacterial 
infections) and deep-seated infections in different organs (such as eye, kidney, liver, spleen, 
brain, bone, abdominal cavity, heart and lung) [4, 14, 17]. 
 
 
2. Epidemiology of IC 
2.1. Causative species 
In most clinical settings, Candida albicans is the most prevalent etiologic agent of IC [4, 
8]. Nevertheless, other non-albicans Candida species, such as Candida glabrata, Candida 
 parapsilosis, Candida tropicalis, Candida krusei (currently known as Pichia kudriavzevii [18]) 
and Candida auris, have recently emerged as major causative species in some high-risk 
populations due to changes in clinical practices [4, 19-21]. More specifically, this shift towards 
other non-albicans Candida species appears to be the result of the selective pressure associated 
with the prophylactic or preemptive use of first-line antifungals that have worked very effectively 
against invasive infections caused by C. albicans, such azoles (in particular, fluconazole) and 
echinocandins [17, 22]. For instance, the emergence of C. glabrata and C. parapsilosis is 
associated with settings with the heavy use of fluconazole and echinocandins, respectively, as 
these non-albicans Candida species are less sensitive to such antifungal agents than C. albicans 
[4, 17]. In view of the different drug susceptibilities of Candida spp., accurate species-specific 
identification is essential for choosing proper antifungal therapy as well as reducing selection 
pressure for antifungal resistance among clinical isolates [1, 4]. 
The distribution of Candida spp. varies considerably over time and with geographical 
location, institution, hospital ward, pre-exposure to antifungal agents, underlying disease or age, 
among other factors [8, 20, 22-23]. For example, C. glabrata is commonly isolated in Northern 
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Europe, the United States and Canada, while C. parapsilosis has emerged as a major cause of IC 
in Southern Europe, South America and Asia [17, 19, 21, 24-25]. In addition, C. glabrata and 
C. parapsilosis are most prominently isolated in the elderly and neonates, respectively [8, 22, 24]. 
The morphological forms observed in infected tissues from IC patients also differ among 
Candida species (Figure 1) [26]. C. glabrata only grows as small yeasts (ovoid-shaped, budding, 
unicellular cells), whereas C. parapsilosis, C. krusei/P. kudriavzevii and C. auris are dimorphic 
fungi capable of exhibiting both yeast forms and pseudohyphal forms (multicellular filaments 
with constrictions at their septa) in clinical lesions [26-27]. In contrast, C. albicans and 
C. tropicalis are polymorphic or pleomorphic fungi that can form yeasts, pseudohyphae and true 
hyphae (multicellular filaments with parallel walls at their septa) in infected tissues and promote 
different stages of the infectious process [13, 15, 26, 28-29]. 
 
2.2. Incidence 
The incidence of IC also varies substantially over time and depending on several factors, 
such as geographic location, local epidemiology, institution, hospital ward, infecting Candida 
spp., underlying condition or age, to name but a few [4, 8, 24]. In particular, its incidence rates 
are more elevated among critically ill and severely immunocompromised patients as well as 
among patients at the extremes of age [8, 17, 24-25, 30]. Diverse population-based surveillance 
studies have revealed annual incidence rates of candidemia of 2-14 cases per 100 000 persons, 
which were higher in the United States than in Europe [8, 24-25, 31-33]. Remarkably, Candida 
spp. were the most common etiologic agents of primary bloodstream infections and the seventh 
leading cause of all healthcare-associated infections, corresponding to 22% and 6%, respectively, 




2.3. Impact on public health 
Unfortunately, IC remains a relentless public health problem worldwide that affects over 
250 000 people every year and accounts for over 50 000 deaths on the basis of conservative 
estimates [8, 17]. This healthcare-associated fungal infection adds significantly to the morbidity 
and mortality of hospitalized patients, especially those with severe underlying conditions (Figure 
2) [8, 17, 35]. Mortality rates among IC patients also differ over time and with infecting Candida 
species, clinical management, institution, hospital ward, underlying diseases or age, among others 
[8, 30, 36-40]. These ranged from 31% to 47% in several epidemiologic and clinical studies 
conducted in different Spanish hospitals [24, 41-42]. Similar trends have also been highlighted in 
the United States and other European countries [1, 8, 25, 35, 43-46]. This infectious disease is 
also responsible for extensive healthcare costs (US $6 214-142 394 per patient), which come 
from longer hospitalizations (ranging between one and several weeks) and more expensive 
antifungal treatments [8, 17, 38-39, 47]. In addition to these elevated hospital costs, IC also 
contributes to substantial societal costs (like lost productivity) [8]. The elevated mortality rates, 
length of hospital stay, as well as hospital and societal costs attributable to IC could considerably 
be minimized by timely initiation of antifungal therapy [8, 24, 36-37]. Each day of delayed 
treatment increases mortality risk around 50% and is associated with an additional US $5 000 in 
healthcare costs [8, 37, 48]. 
 
 
3. Diagnosis of IC 
Early detection is therefore crucial for reducing the impact on patient clinical outcome and 
economic burden of this life-threatening and costly mycosis [8, 24, 36-37]. However, IC is 
extremely difficult to diagnose at an early stage because of its unspecific clinical signs and 
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symptoms (except for Candida endophthalmitis and chorioretinitis), and the insufficient accuracy 
and time delay of the currently available diagnostic methods [4, 8, 14, 30, 49-51] (Figure 2). As a 
consequence, the diagnosis of IC is often reached in advanced stages of infection (where 
antifungal therapy is most likely to fail and patient clinical outcome is poor) or undesirably at 
autopsy [4, 16, 37, 52]. 
The next sections will provide an overview of the currently available tools for the 
diagnosis of IC. These mainly include the current gold standards, nonculture laboratory methods 
based on measurement of pathogen and host-derived biomarkers, clinical prediction scores and 
highly promising leading-edge technologies (Figure 3). Their advantages and disadvantages, as 
well as combined use, will be also discussed. 
 
 
4. The gold standard methods for IC diagnosis 
Fungal culture and tissue histopathology from normally sterile sites remain the gold 
standards to diagnose IC [16]. Owing to their high specificity, a positive result of these 
conventional techniques allows the clinicians to firmly establish a definitive diagnosis of IC and 
thus initiate the administration of antifungal therapy [4, 50]. However, these direct detection 
methods of invasive fungal infection have major drawbacks (Figure 4), which would in part 
account for the persistently elevated morbidity and mortality rates attributable to this 
opportunistic mycosis [8, 37]. 
 
4.1. Fungal culture 
Blood cultures are still the gold standard method for the diagnosis of candidemia (the 
most obvious manifestation of IC) in the absence of or associated with deep-seated candidiasis. 
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On the contrary, these are useless for the detection of deep-seated candidiasis in the absence of 
candidemia [16, 53]. Overall, their sensitivity is too low (21-71%) in the first stages of infection 
and decreases in the presence of nonviable Candida cells [16]. In fact, these can remain negative 
in the presence of antifungal drugs that had been administrated as prophylactic or preemptive 
treatment before blood specimen collection [16, 54-55]. On the other hand, blood cultures can 
take around 2-5 days to achieve conclusive results. More specifically, these require a median time 
to positivity (for fungal growth) from 19 hours for C. tropicalis to 75 hours for C. glabrata, and 
another 24-48 hours for subsequent species-specific identification using conventional methods, 
such as Vitek® 2 YST ID card (bioMérieuxe), AuxaColorTM 2 (Bio-Rad Laboratories), or 
CHROMagarTM Candida (CHROMagar), among others [16, 56-58]. For instance, CHROMagarTM 
Candida is a differential, chromogenic solid medium that allows the presumptive identification of 
clinically important Candida species (Figure 1) [26, 59]. Lamentably, this slow turnaround time 
leads to delayed therapeutic interventions with ensuing poor outcomes of IC patients [37]. 
Fungal cultures from tissue and sterile body fluids (other than blood) collected from deep 
sites of infection are considered the gold standard methods to diagnose deep-seated candidiasis in 
the absence of candidemia [4, 16]. Similar to blood cultures, these are also relatively insensitive 
and time-consuming laboratory techniques [4, 16, 50]. In addition, the invasive procedures 
applied in their sampling are commonly inappropriate or even unfeasible in most patients at risk 
for IC as argued below [53]. 
 
4.2. Tissue histopathology 
Histopathological detection of Candida spp. on biopsy specimens from normally sterile 
sites enables the confirmation of invasive disease as well as an assessment of tissue invasion and 
inflammation [4, 50]. Nevertheless, this conventional method may become particularly invasive 
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and risky in unstable or critically ill patients, or even contraindicated in patients undergoing 
severe thrombocytopenia or coagulopathies [14, 53]. Like fungal cultures, its sensitivity is also 
reduced. This may be attributed to low burdens or uneven distributions of viable Candida cells in 
infected tissues as well as the difficulties encountered in identifying optimal tissue biopsy 
sampling sites [16, 50, 53]. Furthermore, its diagnostic usefulness may also be limited in patients 
who have received prophylactic or preemptive therapy prior to deep tissue biopsy sampling [30]. 
 
 
5. Nonculture laboratory methods for IC diagnosis based on measurement of pathogen-
derived biomarkers 
In an attempt to overcome the main limitations of fungal culture and tissue histopathology 
(Figure 4), diverse alternative laboratory methods (i.e. nonculture-based and minimally invasive 
assays with a quick turnaround time) have been developed and assessed for rapid IC diagnosis 
over the past few decades. These are based on measurement and evaluation of biomarkers derived 
either from the pathogen (Candida nucleic acids, proteins and carbohydrates) or from the host 
(human proteins) in clinical specimens (such as blood, serum, plasma or urine, among other 
samples) from patients at risk for IC (Figure 5) [49, 60-61]. As defined by the Biomarkers 
Definitions Working Group, a biomarker or biological marker is “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention” [62]. 
Although several of these indirect detection methods of invasive fungal infection are 
commercially available, most of them remain investigational (Figure 5). However, none of them 
has shown to be sufficiently accurate or reliable to attain widespread clinical use and improve the 
therapeutic decision-making process on its own as detailed below. This section will survey those 
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based on measurement of Candida biomarkers for early detection of this severe and costly fungal 
infection, while the next section will outline those based on human biomarkers. 
 
5.1. Candida nucleic acids 
5.1.1. Candida DNA 
Many commercial and in-house polymerase chain reaction (PCR)-based assays have been 
developed and evaluated for detection of Candida DNA in diverse biospecimens (such as blood, 
serum, plasma, cerebrospinal fluid and tissues) from patients at risk for IC [50]. These have 
employed a wide variety of DNA targets to diagnose IC, which range from Candida-specific 
genes (such as ERG11, HSP90, SAP1-6, CHS1 or ACT1, among others) to highly-conserved 
multi-copy broad-range panfungal genes (such as 5.8S, 18S or 28S ribosomal sequences or the 
internal transcribed spacer (ITS) 1 or ITS2 regions within the rRNA gene) [1, 14, 63]. In addition 
to these fungus-specific assays, there are also several commercial broader multiplex PCR-based 
assays targeting bacterial and fungal pathogens (including different Candida spp.). These 
multiplex platforms have been applied directly to clinical specimens, such as LightCycler® 
SeptiFast (Roche Diagnostics), SepsiTest™ (Molzym), Magicplex™ system (Seegene), or 
VYOO® (SIRS-Lab), and to positive blood culture bottles, like BioFire FilmArray® 
(bioMérieux), for IC detection [50, 55, 64]. 
Despite their considerably high pooled sensitivity and specificity for IC diagnosis 
reported in a meta-analysis of 54 studies [63], these PCR-based assays have important 
drawbacks. On the one hand, these have not yet been methodologically standardized for routine 
clinical practice nor have they been validated in large multicenter clinical trials, thereby 
hampering their widespread implementation [17, 49]. On the other hand, these assays can yield 
false-negative results because of low numbers of fungal cells in blood as well as complications 
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during sample preparation (e.g., inefficacious cell breakage and DNA extraction due to the 
presence of the fungal cell wall) [32, 39-40, 53]. Likewise, these are also prone to false-positive 
results on account of similarity between fungal and human DNA as well as exogenous sample 
contamination (with DNA from ubiquitous fungal pathogens in buffers, in the environment, on 
utensils and on skin) [4]. 
 
5.2. Candida proteins 
At present, there is only a commercially available assay for measurement and evaluation 
of Candida protein biomarkers in patients at risk for IC. This is a latex agglutination test based on 
the detection of uncharacterized, heat-labile Candida protein antigens in serum (CAND-TEC™; 
Ramco Laboratories, Inc.). Unfortunately, this assay has proven to be low sensitive for IC 
identification [65]. Although several biochemically-defined Candida protein antigens (such as a 
47-kDa fragment of Hsp90, Eno1, Mp65 or Sap1/2, to name but a few) have also been identified 
as potential IC biomarkers in serum, overall antigen detection assays have limited diagnostic 
usefulness for IC [49, 66-71]. Specifically, the detection of Candida protein antigens is seriously 
hindered by their rapid clearance from the bloodstream, formation of immune complexes with 
their related antibodies as well as their low concentrations in the circulation [49]. These 
limitations may, to some extent, be solved by the use of serial determinations for these antigen 
detection assays [70]. 
 
5.3. Candida carbohydrates 
5.3.1. Candida cell wall polysaccharides 
The Candida cell wall is the outermost cellular structure, and is composed of 
(i) polysaccharides, including mannans (32-36%) found solely in covalent association with 
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proteins, ß-D-glucans (47-60%) formed by (1,3)-ß and (1,6)-ß linkages, and chitin (0.6-9%), 
(ii) proteins (6-25%), and (iii) lipids (1-7%) [15, 72]. This basically consists of an elastic three-
dimensional framework of microfibrillar polysaccharides (ß-D-glucans and chitin) that surrounds 
the plasma membrane and to which mannoproteins and proteins are anchored mostly on its 
outside in different ways (Figure 6A) [72-77]. Its two most abundant constituents (mannan and 
(1,3)-ß-D-glucan) are important polysaccharide biomarkers for IC diagnosis, and can be detected 
by several commercial assays as specified below [1, 4]. 
 
5.3.1.1. Candida mannan 
Candida mannan can be measured and evaluated by a latex agglutination test (Pastorex® 
Candida; Bio-Rad Laboratories) or a sandwich enzyme-linked immunosorbent assay (ELISA) 
(Platelia™ Candida Ag Plus; Bio-Rad Laboratories) in serum or plasma from patients at risk for 
IC. Similar to protein antigen detection assays, these have also proven to have low sensitivity to 
diagnose IC [65, 78]. This is mainly because of the high immunogenicity of mannan, which is 
rapidly cleared from the circulation and may also form immune complexes with circulating anti-
mannan antibodies, thereby complicating their assessment [49]. The reduced potential of these 
assays for IC diagnosis can be enhanced by the combined detection of Candida mannan antigen 
(mannanemia) and human anti-mannan antibodies in serum or plasma (see the next section) [79]. 
 
5.3.1.2. Candida (1,3)-ß-D-glucan 
Several commercial assays have also been developed for the detection of circulating 
Candida (1,3)-ß-D-glucan in serum or blood from patients at risk for IC, such as Fungitell® 
(Associates of Cape Cod, Inc.) and Fungitec G-MK® (Seikagaku). These are based on the ability 
of (1,3)-ß-D-glucan to activate a horseshoe crab proteolytic coagulation cascade [80-81]. The 
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Fungitell® assay was approved by the United States Food and Drug Administration (FDA) in 
2004 to assist in IC diagnosis, and remains the most used test in daily clinical practice in Europe 
and the United States [82]. The current European Society of Clinical Microbiology and Infectious 
Diseases (ESCMID) guidelines recommend its use in the diagnosis of candidemia and other 
forms of IC in adults (Figure 6B), and suggest the use of serial determinations to improve its 
clinical performance and rule invasive Candida infection out [82-83].  
Nevertheless these assays have some limitations. Because (1,3)-ß-D-glucan (a major cell 
wall component of many medically important fungi) is a panfungal biomarker of invasive fungal 
infection, this does not discriminate between infections caused by Candida spp. and other fungal 
pathogens, and require further species-specific identification [1, 4, 80]. Furthermore, these assays 
can lead to false-positive results in high-risk populations due to many potential sources of 
contamination. These include human blood products (coagulation factors, immunoglobulins, 
albumin and plasma protein fractions), hemodialysis, high triglycerides, surgical gauzes or other 
glucan-containing materials, excess sample manipulation, certain antibiotics (e.g. intravenous 
amoxicillin-clavulanic acid or piperacillin-tazobactam), some systemic bacterial infections and 
severe mucositis, to name but a few [4, 16, 80, 84-85]. 
 
5.3.2. Candida polyalcohols 
5.3.2.1. Candida D-arabinitol 
D-arabinitol, a metabolite produced by several clinically relevant Candida spp. (except for 
C. glabrata and C. krusei/P. kudriavzevi), has been measured and assessed in serum or urine from 
patients at risk for IC using different techniques [49, 86-88]. These range from gas 
chromatography methods to enzymatic-colorimetric/fluorimetric assays (based on quantification 
of NADH production or NADH-dependent end products) [49, 88].  
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These assays are prone to false-positive results because of the presence of endogenous L-
arabinitol and D-arabinitol (optical isomers or enantiomers) in human serum and urine as well as 
increased serum levels of arabinitol (cleared from the bloodstream by glomerular filtration) in 
patients with renal dysfunction (Figure 7) [49, 88]. The effects of these confounding factors can 
be adjusted by calculating (i) the ratio of D-arabinitol to L-arabinitol (no fungal origin) 
concentrations [89-91], as well as (ii) the ratio of D-arabinitol to creatinine (an indicator of renal 
dysfunction) concentrations [87]. 
On the other hand, these assays do not provide species-level identification for Candida, 
and can also yield false-negative results when D-arabinitol non-producer Candida species are the 
only etiological agents of IC [87-88]. Furthermore, none of these D-arabinitol quantification 
assays has proven to be sufficiently sensitive and specific to diagnose IC on its own [87, 89, 91] 




6. Nonculture laboratory methods for IC diagnosis based on measurement of host-derived 
biomarkers 
As an alternative option to solve the problems associated with conventional diagnostic 
methods for IC (insensitive, time-consuming and invasive techniques; Figure 4), several 
commercial and in-house nonculture laboratory assays based on measurement of host-derived 
biomarkers have also been developed and evaluated in patients at risk for IC over the past 
decades (see above). These biomarkers mainly encompass human antibodies directed against 
Candida protein and carbohydrate antigens, as well as other human proteins related to the host 
response against infection (Figure 5) [4, 61, 92]. Unfortunately, none of these assays has shown 
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to have the diagnostic accuracy necessary to attain widespread implementation on its own as 
discussed below. 
 
6.1. Human antibodies 
Antibody detection assays can lead to false-positive results in healthy individuals (because 
some Candida species are commensal members of human microbiota) as well as false-negative 
results in immunocompromised patients (who may be unable to mount a strong antibody response 
to Candida infection) [49]. These disadvantages may to a certain extent be circumvented by the 
use of (i) more sensitive antibody detection techniques, (ii) infection-specific antigenic protein 
species or antigenic epitopes rather than crude antigens as immunodiagnostic reagents, 
(iii) combinations of several antibody biomarkers, and (iv) combined antigen-antibody detection 
assays, among others [93-99]. 
 
6.1.1. Human antibodies to Candida protein antigens 
There are two commercial C. albicans germ tube antibody (CAGTA) assays for IC 
diagnosis, which are based on an indirect immunofluorescence test [IC (CAGTA) IFA IgG, 
Vircell Microbiologists] and an indirect chemiluminescent immunoassay [IC (CAGTA) VirClia®, 
Vircell Microbiologists]. Both assays detect IgG antibodies to C. albicans cell surface antigens 
from germ tubes. These CAGTA tests have shown high specificity but moderate sensitivity for IC 
identification [100-101]. Nonetheless, several studies have revealed that their combined use with 
(1,3)-ß-D-glucan or mannan detection assays may enhance their diagnostic accuracy [102-104]. 
Diverse in-house immunoassays have also been developed for evaluating serum 
antibodies directed against one or several recombinant C. albicans protein antigens rather than 
crude antigenic protein extracts in patients at risk for IC [67, 94, 98, 105-110]. Despite their 
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potential to assist in IC diagnosis, these assays have not yet been validated in multicenter 
prospective cohort studies. 
 
6.1.2. Human antibodies to Candida carbohydrate antigens 
Circulating anti-mannan antibodies from patients at risk for IC can be measured with a 
commercial indirect ELISA (Platelia™ Candida Ab Plus; Bio-Rad Laboratories). Similar to anti-
Candida protein antibody detection assays, this test has also limited utility for IC diagnosis [79]. 
As aforementioned, the diagnostic accuracy of this biomarker can be improved when this indirect 
ELISA is used in association with its corresponding sandwich ELISA for measurement of 
Candida mannan (Platelia™ Candida Ag Plus) in serum or plasma from patients at risk for IC 
(Figure 8) [79, 91, 99, 111]. The current ESCMID guidelines recommend the combined use of 
these mannan antigen and anti-mannan antibody quantification assays as well as serial 
determinations for both assays in the diagnosis of candidemia and chronic disseminated 
candidiasis but not for other forms of IC (Figure 6B) [82]. 
Because of the potential of IgG2 antibodies against Candida phosphopeptidomannan to 
discriminate IC and heavily colonized patients from non-infected, non-colonized or lightly 
colonized patients, this biomarker could aid clinicians in the initiation of early preemptive 
therapy [112]. However, their diagnostic accuracy has not been compared to the other IgG 
subclass antibodies. In fact, the clinical utility of IgG1, IgG2, IgG3 and IgG4 antibodies to 
Candida proteins and carbohydrates in patients at risk for IC remains to be evaluated. 
 
6.2. Other human proteins 
The diagnostic performance of several human proteins involved in the immune response 
against infection (other than antibodies) and inflammation has also been investigated in patients 
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at risk for IC [61, 65, 103, 113-115]. In particular, procalcitonin (PCT), serum amyloid A (SAA), 
interleukin 17 (IL17), interleukin 23 (IL23) and transforming growth factor ß (TGF-ß), among 
other acute phase proteins and pro-inflammatory cytokines, have been reported as potential 
diagnostic biomarkers for IC [61, 103, 113, 115]. However, these host-derived biomarker 
candidates have not yet proven to be sufficiently accurate to reach widespread clinical use on 
their own, nor have they been validated in large multicenter clinical studies [61, 65, 103]. 
Although their combined use with pathogen-derived biomarkers could enhance their diagnostic 
accuracy for IC, there are apparently contradictory results with the combination of procalcitonin 
with ß-D-glucan testing [65, 114]. 
 
 
7. Clinical prediction algorithms for IC diagnosis 
In the light of the shortcomings associated with the current gold standards and nonculture 
laboratory methods mentioned above, diverse clinical prediction scores, indexes or rules based on 
the combination of multiple independent risk factors for IC have also been devised with the 
intention of identifying patients at risk for IC who may benefit from early therapeutic 
interventions [8, 14, 116]. These include the Candida score, Candida colonization index, 
peritonitis score, candidemia risk score, and other clinical prediction rules [116-124]. For 
example, the Candida score consists of a linear combination of four independent IC risk factors 
(multifocal Candida species colonization, surgery on intensive care unit admission, severe sepsis 
and total parenteral nutrition) with different statistical weights [117]. A prospective multicenter 
study highlighted an irrelevant IC incidence rate in non-neutropenic adult patients that had a 
Candida score of less than 3, had been admitted to the intensive care unit for at least 7 days, and 
had not received antifungal therapy [125]. 
19 
 
In most settings, negative predictive values of these clinical prediction algorithms are 
high, but their positive predictive values are relatively low [8, 30, 116]. Although these tools may 
therefore be useful for ruling IC out and stopping administration of unnecessary prophylactic or 
empirical antifungal therapy, their potential for ruling IC in is reduced. However, their diagnostic 
accuracy may be improved by their combination with IC biomarkers, such as (1,3)-ß-D-glucan, 
CAGTA or procalcitonin, among others, and assessment in at least two consecutive samples 
(Figure 9) [113, 126-127]. 
On the other hand, the scoring systems that draw on colonization data (such as the 
Candida score and colonization index) are work-intensive and expensive, and have limited 
bedside practicability [30, 116]. In addition, their cost-effectiveness for the clinical management 
of IC remains unknown. 
 
 
8. Leading-edge technologies for IC diagnosis 
The past decades have witnessed an increase in the number of cutting-edge technologies 
introduced not only in research but also in the clinical mycology laboratory with the overriding 
intention of reaching a faster and more accurate diagnosis of IC. These are based on molecular, 
proteomic or immunomic approaches. Some of these promising leading-edge technologies are 
commercially available and cleared by the FDA as an aid for IC diagnosis (Figure 10). 
 
8.1. Molecular methods 
Several innovative molecular assays for the detection of Candida species from positive 
blood culture bottles are commercially available. These comprise the Yeast Traffic Light® PNA-
FISH® assay (AdvanDx) and Prove-it™ Sepsis StripArray (Mobidiag) based on a broad-range 
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PCR-coupled microarray (PCR/microarray), to name but a few [64, 128-131]. In particular, the 
Yeast Traffic Light® PNA-FISH® assay is a fluorescent in situ hybridization (FISH) method 
approved by the FDA for IC diagnosis (Figure 10) that utilizes peptide nucleic acid (PNA) probes 
to target Candida-specific rRNA (26S rRNA). This assay allows the rapid and accurate detection 
of five medically important Candida species (C. albicans, C. glabrata, C. parapsilosis, 
C. tropicalis and C. krusei/P. kudriavzevii) directly from positive blood culture bottles [130]. 
Species-specific identification time is therefore reduced from 24-48 hours (using conventional 
methods; see above) to 30-90 min (using this molecular diagnostic method). One of the main 
disadvantages of the PNA-FISH assay is its reliance on positive blood cultures (which can be 
negative in up to 50% of IC cases, and need 19-75 hours for fungal growth [16, 49, 56, 58]). This 
assay may also yield false-negative results when other Candida species are the only causative 
agents of IC. 
In order to solve the problem of dependence on positive blood cultures, leading-edge 
nonculture molecular diagnostic assays have alternatively been developed and evaluated for a 
rapid identification of Candida species directly from clinical samples. These include the 
T2Candida® assay (T2Biosystems) and a broad-range PCR-coupled electrospray ionization mass 
spectrometry platform (PCR/ESI-MS), among others [54-55, 132-133]. The T2Candida® assay is 
a miniaturized molecular method recently cleared by the FDA for rapid diagnosis of IC (Figure 
10) that combines PCR with T2 magnetic resonance (T2MR). This assay enables the detection of 
the amplified DNA (hybridized to iron-decorated nanoparticles) from five clinically relevant 
Candida species (C. albicans, C. glabrata, C. parapsilosis, C. tropicalis and 
C. krusei/P. kudriavzevii) at concentrations of 1-3 colony-forming units per milliliter (CFUs/mL) 
in whole-blood specimens within 3-4 hours [54, 134]. This new nanodiagnostic method has 
shown to be highly sensitive and specific to diagnose candidemia [54, 133-135], and does not 
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need viable Candida cells or sample purification and preparation (unlike blood cultures or other 
biosensors, respectively) [48, 54, 133]. According to economic and outcome modeling studies, 
the T2Candida® assay has the potential to save hospital costs (US $26 887 per patient with 
candidemia) as well as reduce candidemia-related mortality (60.6%) [56, 136]. However, this 
promising molecular diagnostic method has also some shortcomings. This assay relies on the 
prevalence of IC in each clinical setting, and needs further validation in cases of candidemia 
caused by other Candida spp. and deep-seated candidiasis (especially in the absence of 
candidemia) [134]. Furthermore, its costs are elevated (US $350 per sample), the expiration date 
of its reagents is very short, and its sensitivity may decrease in the absence of intact Candida 
cells in whole-blood samples [54, 56].  
 
8.2. Proteomic methods 
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-
TOF MS) has recently emerged as a relevant technology for the identification of wide variety of 
pathogen microorganisms (including Candida species) through their protein mass fingerprints 
[137-142]. VITEK® MS (bioMérieux) and MALDI Biotyper® (Bruker Daltonik GmbH) are 
MALDI-TOF MS instruments approved by the FDA for the diagnosis of IC (Figure 10) [50, 
143]. These systems have several advantages. These take only 10-30 minutes to reach conclusive 
results from positive blood culture bottles, have high accuracy to diagnose IC, are associated with 
low reagent and labor costs, and allow microorganism identification at the species level [50, 137-
138, 140, 144]. All these advantages have led to this proteomic technology replacing 
conventional methods of species-specific identification in most clinical mycology laboratories 
worldwide. However, these accurate, rapid and cost-effective platforms have also some 
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disadvantages. These mainly include their dependence on positive blood cultures (see above), 
spectral database limitations, and high instrument expense [35]. 
 
8.3. Immunomic methods 
Different immunomics-based strategies, such as serological proteome analysis (SERPA), 
recombinant cDNA expression libraries (SEREX), and antigenic protein microarray assays, 
among others, have been developed to search for large panels of potential biomarkers for IC 
diagnosis and evaluate their clinical utility [97, 145-153]. SERPA (which combines high-
resolution two-dimensional gel electrophoresis with Western blotting and mass spectrometry 
[154-156]) has allowed the identification and characterization of many antibody biomarker 
candidates for IC diagnosis, several of which have been validated in appropriate prototype 
immunoassays and have led to encouraging results [93, 98, 146, 157-159]. However, all these 





Over the past decades, a wide variety of rapid, easy and cost-effective methods for the 
detection and identification of Candida species in patients at risk for IC have emerged with the 
unique challenging purpose of minimizing the clinical impact and economic burden of this life-
threatening and costly fungal infection. Despite all these enormous research and development 
efforts, none of these methods has shown to be perfect to diagnose IC nor have they proven to 
reduce the elevated mortality rates, length of hospital stay and healthcare costs attributable to IC. 
However, significant advances have been made in improvement of IC detection. More clinical 
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studies are needed for each assay in larger patient cohorts and many centers to determine its 
diagnostic performance in cases of deep-seated candidiasis (particularly in the absence of 
candidemia), assess its cost-effectiveness and associated management strategies in low and high-
prevalence settings, compare its diagnostic accuracy with other assays, and evaluate the 
diagnostic utility of its combined use with other assays or clinical prediction algorithms, to name 
but a few. Future studies should also be aimed at searching for novel and better strategies that 
allow an early and accurate diagnosis of IC. 
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Figure 1. Different cell morphologies of Candida species in infected tissues from IC patients. 
Depending on Candida species, distinct morphological forms (yeasts, pseudohyphae 
and/or hyphae) can be found in clinical lesions from IC patients. All of them are pathogenic and 
can promote different stages of infectious process. Asterisk indicates that C. krusei (currently 
known as P. kudriavzevii) is now considered a member of the genus Pichia rather than the genus 
Candida [18]. CHROMagarTM Candida is a differential, chromogenic solid medium used for 
presumptive identification of clinically relevant Candida spp. from positive (blood) culture 
bottles. Dagger denotes that C. auris isolates show white to cream colored smooth colonies on 
CHROMagarTM Candida medium supplemented with Pal’s agar, and can be discriminated from 
isolates identified as Candida haemulonii by other conventional method (Vitek® 2 YST ID card) 
[59]. See text for further information. CFU, colony-forming unit. 
 
Figure 2. Overview of the current clinical setting for human IC. 
IC remains a major infectious cause of morbidity and mortality in critically ill and 
severely immunocompromised patients, and further accounts for substantial healthcare costs. 
Data on its clinical impact and economic burden are from [1, 4, 8, 16-17, 34, 48, 161-163]. See 
text for further details. BSI, bloodstream infections; HAI, healthcare-associated infections. 
 
Figure 3. Currently available methods for IC diagnosis. 
Diverse methods have been developed and evaluated for IC diagnosis. These encompass 
the gold standards, nonculture laboratory tests based on measurement of pathogen and host-
derived biomarkers, clinical prediction tools, and leading-edge technologies. See text for further 
information. PCR, polymerase chain reaction; CAGTA, Candida albicans germ tube antibody; 
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PCT, procalcitonin; SAA, serum amyloid A; IL17, interleukin 17; PNA-FISH, peptide nucleic 
acid-fluorescent in situ hybridization; MALDI-TOF, matrix-assisted laser desorption-ionization 
time-of-flight; MS, mass spectrometry. 
 
Figure 4. Main advantages and disadvantages of the current gold standard methods for IC 
diagnosis. 
The current gold standards to diagnose IC include fungal culture and tissue histopathology 
from normally sterile sites. The main advantage of these direct detection techniques of invasive 
fungal infection is their high specificity, whereas their major disadvantages are their low 
sensitivity, slow turnaround times (*except for tissue histopathology) and invasive testing 
(*except for blood culture). See text for further details. 
 
Figure 5. Main pathogen and host-derived biomarkers for IC diagnosis. 
Shaded rectangle shows the main commercially available tests for IC diagnosis based on 
measurement of Candida or human biomarkers. Asterisk indicates FDA-cleared assay to diagnose 
IC (see Figure 10). Line with arrowhead at both ends depicts those commercial diagnostic tests 
used in combination in clinical practice. See text for further information. rRNA, ribosomal RNA; 
ERG11, cytochrome P450 lanosterol 14-α-demethylase gene; CHS1, chitin synthase gene; Hsp90, 
90-kDa heat shock protein; Eno1, enolase; Mp65, 65-kDa mannoprotein; Sap1/2, secreted 
aspartyl proteinase 1/2; Ag, antigen; Ab, antibodies; CAGTA, Candida albicans germ tube 
antibody; IFA, immunofluorescence assay; IgG, immunoglobulin G; PCT, procalcitonin; SAA, 





Figure 6. Candida cell wall polysaccharides as diagnostic biomarkers for IC. 
A. Schematic representation of the C. albicans cell envelope. This encompasses an outer 
cell wall and an inner plasma membrane. The cell wall is basically composed of polysaccharides 
(mannan, ß-D-glucan and chitin) and proteins. Mannan and (1,3)-ß-D-glucan are its two most 
abundant constituents and major polysaccharide biomarkers for IC diagnosis, which can be 
detected by several commercial assays [1, 4]. See text for details. B. ESCMID-proposed 
recommendations about the use of gold standards, mannan/anti-mannan assays and ß-D-glucan 
assay for the diagnosis of candidemia, chronic disseminated candidiasis and other forms of IC in 
adults [82]. The use of mannan/anti-mannan assays is recommended in the diagnosis of 
candidemia and chronic disseminated candidiasis but not for other forms of IC, while the use of 
ß-D-glucan assay is recommended in the diagnosis of all these conditions. 
 
Figure 7. Candida D-arabinitol as a diagnostic biomarker for IC. 
L-arabinitol and D-arabinitol are enantiomers (optical isomers) that are present in human 
body fluids (urine and serum). Several medically important Candida species (*with the exception 
of C. glabrata and C. krusei/P. kudriavzevi) produce D-arabinitol (a five-carbon sugar alcohol). 
D-arabinitol quantification assays for IC diagnosis have been associated with false-positive 
results. The possible sources for false positivity (confounding factors) can be corrected by 
calculating relative amounts of D-arabinitol and L-arabinitol as well as D-arabinitol and 
creatinine (an indicator of renal dysfunction). Brackets represent concentration. See text for 
further details. 
 
Figure 8. Mannan antigen and anti-mannan antibody quantification assays for IC diagnosis. 
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The combined use of both commercially available assays provides better discrimination 
between IC and non-IC patients than the individual assays alone. See text for further information. 
Ag, antigen; Ab, antibody; HRP, horseradish peroxidase; mAb, monoclonal antibody; EBCA-1, 
antibody directed against Candida (1-5)-α-oligomannosides; pAb, polyclonal antibody; ELISA, 
enzyme-linked immunosorbent assay. 
 
Figure 9. Early diagnostic algorithm to identify patients at high risk for IC who may benefit from 
empirical antifungal therapy. 
This algorithm is based on the combination of clinical scores with IC biomarkers (in 
particular, (1,3)-ß-D-glucan evaluated alone or in combination with CAGTA or procalcitonin, 
among other IC biomarkers, in two consecutive samples) [113, 126-127]. Empirical antifungal 
therapy is administrated in the absence of positive cultures in high-risk patients who manifest 
clinical signs and symptoms of infection [8]. See text for further details. 
 
Figure 10. Comparison of the FDA-approved methods for IC diagnosis. 
At present there are several methods cleared by the FDA to assist in the diagnosis of IC. 
These include culture-independent (Fungitell® and T2Candida®) and blood culture-dependent 
(Yeast Traffic Light® PNA-FISH®, VITEK® MS and MALDI Biotyper®) assays. Asterisk 
indicates that one of the five Candida species that can be detected with T2Candida® or Yeast 
Traffic Light® PNA-FISH® assays, i.e. C. krusei (currently known as P. kudriavzevii), is now 
considered a member of the genus Pichia rather than the genus Candida [18]. See text for further 
information. FDA, Food and Drug Administration; T2RM, T2 magnetic resonance; PNA-FISH, 
peptide nucleic acid-fluorescent in situ hybridization; MALDI-TOF, matrix-assisted laser 
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desorption/ionization time-of-flight; MS, mass spectrometry; CFU, colony-forming unit; ITS2, 
internal transcribed spacer 2; rRNA, ribosomal RNA. 
